Loading
Several studies found patients infused with checkpoint inhibitors earlier in the day lived longer. If a randomised trial confirms it, it is a free improvement available everywhere tomorrow.
This idea proposes giving immunotherapy in the morning: patients infused with checkpoint inhibitors earlier in the day lived longer in several studies, and a randomised trial could confirm a free improvement. Retrospective cohorts (Lancet Oncology 2021 and follow-ups) and the small randomised MEMOIR signal associate morning infusions with better survival, plausibly through circadian T-cell trafficking (Circadian control pathway). The hypothesis is that infusing Immune checkpoint inhibitors against PD-1 before midday improves overall survival compared with afternoon infusions, backed by consistent cohort data and mouse immunology. The test is a large pragmatic randomised trial of morning against afternoon infusion in first-line PD-1 therapy for Non-small-cell lung cancer and Melanoma.
One pathway page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for PD-1 in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.
Shares CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, CheckMate 915, RELATIVITY-098, Fianlimab + cemiplimab phase 3 (first-line melanoma) and the tags mechanism, open-question.
Shares Gustave Roussy, PD-1 / PD-L1 immune checkpoint & T-cell activation, Memorial Sloan Kettering Cancer Center, PD-1 and the tags mechanism, open-question.
Shares Memorial Sloan Kettering Cancer Center, Non-small-cell lung cancer and the tags mechanism, open-question.
Shares Memorial Sloan Kettering Cancer Center, Melanoma and the tags mechanism, open-question.
Shares Melanoma, Non-small-cell lung cancer and the tags mechanism, open-question.
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.